NR3C2 and kidney disorder: Antagonizing the overactivation of the MR is a therapeutic strategy largely studied in cardiovascular [7,8,9,10] and kidney diseases models [11,12,13,14], showing the benefit of using mineralocorticoid receptor antagonists (MRA) to delay the progression of the disease.